

Bernard Ce Khoo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4418217/publications.pdf>

Version: 2024-02-01

54
papers

2,176
citations

304602

22
h-index

223716

46
g-index

56
all docs

56
docs citations

56
times ranked

3530
citing authors

#	ARTICLE	IF	CITATIONS
1	Mutations in MRAP, encoding a new interacting partner of the ACTH receptor, cause familial glucocorticoid deficiency type 2. <i>Nature Genetics</i> , 2005, 37, 166-170.	9.4	388
2	Association between high serum total cortisol concentrations and mortality from COVID-19. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 659-660.	5.5	193
3	Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families. <i>Human Mutation</i> , 2010, 31, 950-960.	1.1	154
4	Landscape of Familial Isolated and Young-Onset Pituitary Adenomas: Prospective Diagnosis in AIP Mutation Carriers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E1242-E1254.	1.8	144
5	Thyroid Function Before, During, and After COVID-19. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e803-e811.	1.8	143
6	Delivery is key: lessons learnt from developing splice-switching antisense therapies. <i>EMBO Molecular Medicine</i> , 2017, 9, 545-557.	3.3	119
7	Somatostatin Infusion Lowers Plasma Ghrelin without Reducing Appetite in Adults with Prader-Willi Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 4162-4165.	1.8	113
8	Clinical manifestations of familial paraganglioma and pheochromocytomas in succinate dehydrogenase B (SDHB) gene mutation carriers. <i>Clinical Endocrinology</i> , 2008, 69, 587-596.	1.2	81
9	Peptide Receptor Radionuclide Treatment and (131)I-MIBG in the management of patients with metastatic/progressive pheochromocytomas and paragangliomas. <i>Journal of Surgical Oncology</i> , 2017, 115, 425-434.	0.8	64
10	Development of Therapeutic Splice-Switching Oligonucleotides. <i>Human Gene Therapy</i> , 2014, 25, 587-598.	1.4	59
11	Normal Adrenal and Thyroid Function in Patients Who Survive COVID-19 Infection. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 2208-2220.	1.8	50
12	Peptide Receptor Radionuclide Therapy as a Novel Treatment for Metastatic and Invasive Pheochromocytoma and Paraganglioma. <i>Neuroendocrinology</i> , 2019, 109, 287-298.	1.2	48
13	Real-life experience of tolvaptan use in the treatment of severe hyponatraemia due to syndrome of inappropriate antidiuretic hormone secretion. <i>Clinical Endocrinology</i> , 2016, 84, 620-626.	1.2	46
14	Redefining the stress cortisol response to surgery. <i>Clinical Endocrinology</i> , 2017, 87, 451-458.	1.2	46
15	Antisense oligonucleotide-induced alternative splicing of the APOB mRNA generates a novel isoform of APOB. <i>BMC Molecular Biology</i> , 2007, 8, 3.	3.0	44
16	Regulation of CYP27B1 and CYP24A1 hydroxylases limits cell-autonomous activation of vitamin D in dendritic cells. <i>European Journal of Immunology</i> , 2014, 44, 1781-1790.	1.6	41
17	Pre-Spliceosomal Binding of U1 Small Nuclear Ribonucleoprotein (RNP) and Heterogenous Nuclear RNP E1 Is Associated with Suppression of a Growth Hormone Receptor Pseudoexon. <i>Molecular Endocrinology</i> , 2007, 21, 2529-2540.	3.7	36
18	Contrasting clinical manifestations of SDHB and VHL associated chromaffin tumours. <i>Endocrine-Related Cancer</i> , 2009, 16, 515-525.	1.6	35

#	ARTICLE	IF	CITATIONS
19	Splicing modulation therapy in the treatment of genetic diseases. <i>The Application of Clinical Genetics</i> , 2014, 7, 245.	1.4	33
20	Exon Skipping of Hepatic APOB Pre-mRNA With Splice-switching Oligonucleotides Reduces LDL Cholesterol In Vivo. <i>Molecular Therapy</i> , 2013, 21, 602-609.	3.7	26
21	Multicentre study of investigation and management of inpatient hyponatraemia in the UK. <i>Postgraduate Medical Journal</i> , 2014, 90, 694-698.	0.9	25
22	Assessment and Management of Anti-Insulin Autoantibodies in Varying Presentations of Insulin Autoimmune Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 3845-3855.	1.8	24
23	Splicing therapeutics in SMN2 and APOB. <i>Current Opinion in Molecular Therapeutics</i> , 2009, 11, 108-15.	2.8	24
24	Cell-type-specific modulation of innate immune signalling by vitamin D in human mononuclear phagocytes. <i>Immunology</i> , 2017, 150, 55-63.	2.0	23
25	Proglucagon peptide secretion profiles in type 2 diabetes before and after bariatric surgery: 1-year prospective study. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001076.	1.2	18
26	Combination gut hormones: prospects and questions for the future of obesity and diabetes therapy. <i>Journal of Endocrinology</i> , 2020, 246, R65-R74.	1.2	18
27	Distinct patterns of heparan sulphate in pancreatic islets suggest novel roles in paracrine islet regulation. <i>Molecular and Cellular Endocrinology</i> , 2015, 399, 296-310.	1.6	17
28	Phaeochromocytomas and Paragangliomas: A difference in disease behaviour and clinical outcomes. <i>Journal of Surgical Oncology</i> , 2015, 112, 486-491.	0.8	15
29	Metastatic Medullary Thyroid Cancer: The Role of 68Gallium-DOTA-Somatostatin Analogue PET/CT and Peptide Receptor Radionuclide Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e4903-e4916.	1.8	15
30	MELAS syndrome, diabetes and thyroid disease: the role of mitochondrial oxidative stress. <i>Clinical Endocrinology</i> , 2009, 70, 340-341.	1.2	12
31	Repair of Aberrant Splicing in Growth Hormone Receptor by Antisense Oligonucleotides Targeting the Splice Sites of a Pseudoexon. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 3542-3546.	1.8	10
32	Safety and efficacy of an extended-release peptide <sc>YY</sc> analogue for obesity: A randomized, placebo-controlled, phase <sc>1</sc> trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1471-1483.	2.2	9
33	Roux-en-Y Gastric Bypass Increases Glycemic Variability and Time in Hypoglycemia in Patients With Obesity and Prediabetes or Type 2 Diabetes: A Prospective Cohort Study. <i>Diabetes Care</i> , 2021, 44, 614-617.	4.3	9
34	Differential effects of bile acids on the postprandial secretion of gut hormones: a randomized crossover study. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2021, 320, E671-E679.	1.8	8
35	Malignant Somatostatinoma Presenting with Diabetic Ketoacidosis and Inhibitory Syndrome: Pathophysiologic Considerations. <i>Endocrine Practice</i> , 2010, 16, 835-837.	1.1	8
36	Preserved <sc>C</sc>-peptide in survivors of <sc>COVID</sc>-19: Post hoc analysis. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 570-574.	2.2	8

#	ARTICLE	IF	CITATIONS
37	Putting some spine into alternative splicing. Trends in Biotechnology, 2003, 21, 328-330.	4.9	7
38	Antisense-Mediated Exon-Skipping to Induce Gene Knockdown. Methods in Molecular Biology, 2012, 867, 289-305.	0.4	7
39	Renin-Angiotensin System Blockade Improves Cardiac Indices in Acromegaly Patients. Experimental and Clinical Endocrinology and Diabetes, 2017, 125, 365-367.	0.6	7
40	Radiology reporting of adrenal incidentalomas â€“ who requires further testing?. Clinical Medicine, 2014, 14, 16-21.	0.8	6
41	Cortisol concentrations and mortality from COVID-19 â€“ Authors' reply. Lancet Diabetes and Endocrinology, the, 2020, 8, 809-810.	5.5	6
42	â€“Running on emptyâ€™. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1439-1440.	3.3	5
43	Genetic therapies to lower cholesterol. Vascular Pharmacology, 2015, 64, 11-15.	1.0	5
44	Pancreatic Adenocarcinoma in a Patient With Multiple Endocrine Neoplasia 1 Syndrome. Pancreas, 2013, 42, 725-726.	0.5	4
45	Inflammatory myofibroblastic tumour arising in the adrenal gland: a case report. Journal of Medical Case Reports, 2014, 8, 411.	0.4	4
46	Once-daily, modified-release hydrocortisone in patients with adrenal insufficiency. Lancet Diabetes and Endocrinology, the, 2018, 6, 269.	5.5	4
47	Tirzepatide and the new era of twincretins for diabetes. Lancet, The, 2021, 398, 95-97.	6.3	4
48	Understanding the treatment algorithm of patients with metastatic pancreatic neuroendocrine neoplasms: A single-institution retrospective analysis comparing outcomes of chemotherapy, molecular targeted therapy and peptide receptor radionuclide therapy in 255 patients. Neuroendocrinology, 2020, 111, 863-875.	1.2	3
49	Surpassing insulin glargine in type 2 diabetes with tirzepatide. Lancet, The, 2021, 398, 1779-1781.	6.3	3
50	Ockhamâ€™s Razor for a Retinal Lesion and Acromegaly and Breaking the Vicious Circle. Journal of the Endocrine Society, 2022, 6, .	0.1	2
51	Multiple tandem splicing silencer elements suppress aberrant splicing within the long exon 26 of the human Apolipoprotein B gene. BMC Molecular Biology, 2013, 14, 5.	3.0	1
52	Misleading ⁶⁸ GALLIUMâ€“dotatate PET scan in a patient with a history of a pheochromocytoma: Unsuspected uptake in papillary thyroid carcinoma metastases. Journal of Neuroendocrinology, 2021, 33, e12964.	1.2	1
53	A Comparison of the Blood Glucose, Growth Hormone, and Cortisol Responses to Two Doses of Insulin (0.15â€“U/kg vs. 0.10â€“U/kg) in the Insulin Tolerance Test: A Single-Centre Audit of 174 Cases. International Journal of Endocrinology, 2022, 2022, 1-8.	0.6	1
54	Steps to redressing an imbalance: GLP-1 analogues for obesity in east Asia. Lancet Diabetes and Endocrinology, the, 2022, , .	5.5	0